Construction of tumor-specific toxins using ubiquitin fusion technique

Molecular Therapy

Volumn 11, Issue 2, 2005, Pages 196-204

  Tcherniuk, Sergey O ^a   Chroboczek, Jadwiga ^a   Balakirev, Maxim Y ^a,b  

^a INSTITUT DE BIOLOGIE STRUCTURALE   (France)

^b CEA GRENOBLE   (France)

Author keywords

Prostate tumor; Prostate specific antigen; Protease; Protein degradation; Ribosome inactivating proteins; Saporin; Ubiquitin fusion

Indexed keywords

CYTOTOXIC AGENT; PROSTATE SPECIFIC ANTIGEN; PROTEINASE; SAPORIN;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; UBIQUITINATION;

CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; MALE; PLANT PROTEINS; PROSTATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS; RETICULOCYTES; SAPONARIA; SENSITIVITY AND SPECIFICITY; TOXINS, BIOLOGICAL; UBIQUITIN;

INSERTION SEQUENCES; SAPONARIA; SAPONARIA OFFICINALIS;

EID: 12744278656     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.10.009     Document Type: Article

References (59)

1. J. Gulley W.L. Dahut Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient Urology 62 2003 147-154
2. H. Lilja A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein J. Clin. Invest. 76 1985 1899-1903
3. H. Lilja Biology of prostate-specific antigen Urology 62 2003 27-33
4. T.A. Stamey N. Yang A.R. Hay J.E. McNeal F.S. Freiha E. Redwine Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N. Engl. J. Med. 317 1987 909-916
5. M. Levesque H. Yu M. D'Costa E. Diamandis Prostate specific antigen expression by various tumors J. Clin. Lab. Anal. 9 1995 123-128
6. W.J. Catalona et al., Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial JAMA 279 1998 1542-1547
7. P. Finne et al., Use of the complex between prostate specific antigen and α1-protease inhibitor for screening prostate cancer J. Urol. 164 2000 1956-1960
8. S.F. Shariat E.I. Canto M.W. Kattan K.M. Slawin Beyond prostate-specific antigen: New serologic biomarkers for improved diagnosis and management of prostate cancer Rev. Urol. 6 2004 58-72
9. P.A. Humphrey D.W. Keetch D.S. Smith D.L. Shepherd W.J. Catalona Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening J. Urol. 155 1996 816-820
10. W.J. Peumans Q. Hao E.J. Van Damme Ribosome-inactivating proteins from plants: More than RNA N-glycosidases? FASEB J. 15 2001 1493-1506
11. J.E. Smallshaw et al., Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice Nat. Biotechnol. 21 2003 387-391
12. L. Barbieri A. Bolognesi F. Stirpe Purification and conjugation of type 1 ribosome-inactivating proteins Methods Mol. Biol. 166 2001 71-85
13. M.G. Rosenblum J.W. Marks L.H. Cheung Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin Cancer Chemother. Pharmacol. 44 1999 343-348
14. M.S. Fabbrini D. Carpani I. Bello-Rivero M.R. Soria The amino-terminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: Internalization is toxin mediated FASEB J. 13 1997 1169-1176
15. L. Qi et al., Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptor Cancer Res. 64 2004 2090-2095
16. M.L. Nichols et al., Transmission of chronic nociception by spinal neurons expressing the substance P receptor Adv. Drug Delivery Rev. 55 2003 1043-1054
17. F. Porreca et al., Inhibition of neuropathic pain by selective ablation of brainstem medullary cells expressing the mu-opioid receptor J. Neurosci. 21 2001 5281-5288
18. R.G. Wiley D.A. Lappi Targeted toxins in pain Adv. Drug Delivery Rev. 55 2003 1043-1054
19. M.S. Fabbrini et al., Characterization of a saporin isoform with lower ribosome-inhibiting activity Biochem. J. 322 1997 719-727
20. D.J. Flavell Saporin immunotoxins Curr. Top. Microbiol. Immunol. 234 1998 57-61
21. A. Hershko A. Ciechanover The ubiquitin system Annu. Rev. Biochem. 67 1998 425-479
22. E.S. Johnson B. Bartel W. Seufert A. Varshavsky Ubiquitin as a degradation signal EMBO J. 11 1992 497-505
23. E.S. Johnson P.C. Ma I.M. Ota A. Varshavsky A proteolytic pathway that recognizes ubiquitin as a degradation signal J. Biol. Chem. 270 1995 17442-17456
24. J.H. Kim K.C. Park S.S. Chung O. Bang C.H. Chung Deubiquitinating enzymes as cellular regulators J. Biochem. 134 2003 9-18
25. A. Guterman M.H. Glickman Deubiquitinating enzymes are IN/(trinsic to proteasome function) Curr. Protein Pept. Sci. 5 2004 201-211
26. G.C. Turner A. Varshavsky Detecting and measuring cotranslational protein degradation in vivo Science 289 2000 2117-2120
27. N.P. Dantuma K. Lindsten R. Glas M. Jellne M.G. Masucci Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells Nat. Biotechnol. 18 2000 538-543
28. J.H. Stack M. Whitney S.M. Rodems B.A. Pollok A ubiquitin-based tagging system for controlled modulation of protein stability Nat. Biotechnol. 18 2000 1298-1302
29. G.S. Coombs et al., Substrate specificity of prostate-specific antigen (PSA) Chem. Biol. 5 1998 475-488
30. M.L. Hale Microtiter-based assay for evaluating the biological activity of ribosome-inactivating proteins Pharmacol. Toxicol. 88 2001 255-260
31. A. Hershko H. Heller S. Elias A. Ciechanover Components of ubiquitin-protein ligase system: Resolution, affinity purification, and role in protein breakdown J. Biol. Chem. 258 1983 8206-8214
32. S. Santanche A. Bellelli M. Brunori The unusual stability of saporin, a candidate for the synthesis of immunotoxins Biochem. Biophys. Res. Commun. 234 1997 129-132
33. P.O. Falnes S. Olsnes Modulation of the intracellular stability and toxicity of diphtheria toxin through degradation by the N-end rule pathway EMBO J. 17 1998 615-625
34. B.P. Monia et al., Gene synthesis, expression, and processing of human ubiquitin carboxyl extension proteins J. Biol. Chem. 264 1989 4093-4103
35. R. Ippoliti et al., Endocytosis of a chimera between human pro-urokinase and the plant toxin saporin: An unusual internalization mechanism FASEB J. 14 2000 1335-1344
36. U. Cavallaro A. Nykjaer M. Nielsen M.R. Soria Alpha 2-macroglobulin receptor mediates binding and cytotoxicity of plant ribosome-inactivating proteins Eur. J. Biochem. 232 1995 165-171
37. S. Bagga M.V. Hosur J.K. Batra Cytotoxicity of ribosome-inactivating protein saporin is not mediated through alpha2-macroglobulin receptor FEBS Lett. 541 2003 16-20
38. A.M. Mansour et al., A new approach for the treatment of malignant melanoma: Enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2 Cancer Res. 63 2003 4062-4066
39. D. DeFeo-Jones et al., A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo Nat. Med. 6 2000 1248-1252
40. S.R. Denmeade et al., Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer J. Natl. Cancer Inst. 95 2003 990-1000
41. L. Devy et al., Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity FASEB J. 18 2004 565-567
42. S. Liu H. Aaronson D.J. Mitola S.H. Leppla T.H. Bugge Potent antitumor activity of a urokinase-activated engineered anthrax toxin Proc. Natl. Acad. Sci. USA 100 2003 657-662
43. M.G. Jobling R.K. Holmes Biological and biochemical characterization of variant A subunits of cholera toxin constructed by site-directed mutagenesis J. Bacteriol. 183 2001 4024-4032
44. P.O. Falnes R. Welker H.G. Krausslich S. Olsnes Toxins that are activated by HIV type-1 protease through removal of a signal for degradation by the N-end-rule pathway Biochem. J. 343 1999 199-207
45. A. Varshavsky The N-end rule Cold Spring Harbor Symp. Quant. Biol. 60 1995 461-478
46. A. Varshavsky G. Turner F. Du Y. Xie Felix Hoppe-Seyler Lecture 2000. The ubiquitin system and the N-end rule pathway Biol. Chem. 381 2000 779-789
47. A.M. Vocero-Akbani N.V. Heyden N.A. Lissy L. Ratner S.F. Dowdy Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein Nat. Med. 5 1999 29-33
48. E.C. Hsu et al., Modified apoptotic molecule (BID) reduces hepatitis C virus infection in mice with chimeric human livers Nat. Biotechnol. 21 2003 519-525
49. C. Savino L. Federici R. Ippoliti E. Lendaro D. Tsernoglou The crystal structure of saporin SO6 from Saponaria officinalis and its interaction with the ribosome FEBS Lett. 470 2000 239-243
50. F. Mannello M. Malatesta F. Luchetti S. Papa S. Battistelli G. Gazzanelli Immunoreactivity, ultrastructural localization, and transcript expression of prostate-specific antigen in human neuroblastoma cell lines Clin. Chem. 45 1999 78-84
51. S.M. Dhanasekaran et al., Delineation of prognostic biomarkers in prostate cancer Nature 412 2001 822-826
52. J.B. Welsh et al., Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer Cancer Res. 61 2001 5974-5978
53. A. Varshavsky Codominance and toxins: A path to drugs of nearly unlimited selectivity Proc. Natl. Acad. Sci. USA 92 1995 3663-3667
54. X. Huang M. Bennett P.E. Thorpe Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen Prostate 61 2004 1-11
55. S.S. Chang Monoclonal antibodies and prostate-specific membrane antigen Curr. Opin. Invest. Drugs 5 2004 611-615
56. J.P. Latham P.F. Searle V. Mautner N.D. James Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector Cancer Res. 60 2000 334-341
57. W.S. Cheng et al., A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer Mol. Ther. 10 2004 355-364
58. J.M. Zhou S. Fujita M. Warashina T. Baba K. Taira A novel strategy by the action of ricin that connects phenotype and genotype without loss of the diversity of libraries J. Am. Chem. Soc. 124 2002 538-543
59. S.C. Johnston S.M. Riddle R.E. Cohen C.P. Hill Structural basis for the specificity of ubiquitin C-terminal hydrolases EMBO J. 18 1999 3877-3887